Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

VIGI-4: Development of a Novel Pharmacovigilance Method Using ChatGPT

Version 1 : Received: 6 April 2024 / Approved: 8 April 2024 / Online: 8 April 2024 (11:16:12 CEST)

How to cite: Teperikidis, E.; Papazisis, G. VIGI-4: Development of a Novel Pharmacovigilance Method Using ChatGPT. Preprints 2024, 2024040523. https://doi.org/10.20944/preprints202404.0523.v1 Teperikidis, E.; Papazisis, G. VIGI-4: Development of a Novel Pharmacovigilance Method Using ChatGPT. Preprints 2024, 2024040523. https://doi.org/10.20944/preprints202404.0523.v1

Abstract

This study proposes an innovative pharmacovigilance approach, VIGI-4, leveraging ChatGPT Teams Pro version. Our method involves aggregating data from all phase 4 studies published in February 2024 to identify adverse reactions. These results are categorized by disease state alphabetically, demonstrating the method's capacity to generate structured and easily navigable outputs. The results section is tailored to exemplify the valuable, actionable insights attainable through our workflow. This research emphasizes the game-changing potential of integrating advanced technologies such as ChatGPT into pharmacovigilance, signaling a new era in safeguarding drug safety.

Keywords

pharmacovigilance; adverse drug reactions; ChatGPT; artificial intelligence; phase 4 studies; drug safety

Subject

Medicine and Pharmacology, Pharmacology and Toxicology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.